28
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7318 |
Elimusertib
BAY-1895344 |
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
Elimusertib (BAY-1895344) 是一种可口服的选择性ATR 抑制剂,IC50值为 7 nM。它具有抗肿瘤活性,可研究实体瘤和淋巴瘤。 | |||
T76707 |
Brentuximab vedotin
SGN-35 |
Others | Others |
Brentuximab vedotin (SGN-35) 是一种靶向 CD30 的抗体-活性分子偶联物 (ADC),具有抗肿瘤活性,可研究淋巴瘤。 | |||
T0707L |
Cyclophosphamide
|
DNA Alkylator/Crosslinker; DNA; MRP | DNA Damage/DNA Repair; Immunology/Inflammation |
Cyclophosphamide 是一种烷化剂,具有抗肿瘤及免疫抑制活性,用于治疗多种癌症。 | |||
T73140 |
MAT2A-IN-9
|
Methionine Adenosyltransferase (MAT) | Chromatin/Epigenetic |
MAT2A-IN-9 是一种 2-oxoquinazoline 衍生物,是一种有效的MAT2A (蛋氨酸腺苷转移酶 2A) 抑制剂。MAT2A-IN-9 具有抗肿瘤活性可用于治疗淋巴瘤和实体瘤。 | |||
T8380 |
Bendamustine
SDX105,宾达氮芥 |
Apoptosis; Others; DNA Alkylator/Crosslinker | Apoptosis; DNA Damage/DNA Repair; Others |
Bendamustine (SDX105) 是一种嘌呤类似物,是一种 DNA 交联剂,具有烷基化、抗癌和抗代谢作用。它可激活 DNA 损伤反应和细胞凋亡。 | |||
T76685 |
Glofitamab
RO7082859,RG 6026,CD20-TCB |
Others | Others |
Glofitamab (RO7082859) 是一种新型针对 CD20 结合 T 细胞的二价抗体。Glofitamab 通过与恶性细胞上的 CD20 结合促使 T 细胞增殖活化和肿瘤细胞杀伤。Glofitamab 可用于缓解复发或难治性 B 细胞淋巴瘤。 | |||
T70388 |
(S)-Enitociclib
VIP152 |
CDK | Cell Cycle/Checkpoint |
(S)-Enitociclib (VIP152) 是一种选择性 CDK9 抑制剂,通过抑制 RNA 聚合酶 II 介导的转录来诱导 MYC+ 淋巴瘤的完全消退,抑制抗凋亡和促生存蛋白的转录。 | |||
T16702 |
QL47
|
Virus Protease; BTK | Angiogenesis; Microbiology/Virology; Tyrosine Kinase/Adaptors |
QL47 是一种宿主靶向的小分子抗病毒剂,具有抗病毒活性,对登革热病毒和其他 RNA 病毒有抑制作用。QL47 可作为病毒翻译的抑制抑制剂和 BTK 的共价抑制剂,可用于研究淋巴瘤。 | |||
T73400L |
PG-11047 2HCl
PG-11047 2HCl(949933-50-0 Free base),CGC-11047 2HCl |
Apoptosis | Apoptosis |
PG-11047 2HCl 是一种细胞凋亡刺激剂,可用于治疗泌尿生殖系统疾病、免疫系统疾病、遗传病与畸形、眼部疾病和血液及淋巴系统疾病,研究淋巴瘤和前列腺癌。 | |||
T23872 |
Cellocidin
NSC65381,NSC# 65381,NSC-65381,NSC#65381,NSC 65381 |
||
Cellocidin is a potent gammaherpesvirus-associated B-lymphomas growth inhibitor. It acts through the activation of both the NF-κB and c-Myc-mediated signaling pathways. | |||
T24548 |
NSC10010 hydrochloride
NSC#10010,NSC 10010,NSC# 10010,NSC#-10010,NSC-10010 |
||
NSC10010 hydrochloride is an effective growth inhibitor for gammaherpesvirus-associated B-lymphomas. It acts through activation of both the NF-κB and c-Myc-mediated signaling pathways. | |||
T74096 | Prednimustine | ||
Prednimustine (Leo 1031;NSC 134087) 是由 Prednisolone 和 Chlorambucil 形成的酯。Prednimustine 可用于白血病和淋巴瘤的研究。 | |||
T61084 |
Tubulin polymerization-IN-37
|
||
Tubulin polymerization-IN-37 is a potent inhibitor (IC50: 2.3 μΜ) of tubulin polymerization by binding specifically to the colchicine site of tubulin and preventing colchicine binding. It has potential applications in cancer research, notably for lymphomas [1]. | |||
T70563 |
KC-11404
|
||
KC-11404 is an LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor and 5-lipoxygenase. | |||
T26754 |
BC-23
NSC 45382,BC 23,BC23,NSC-45382,NSC45382 |
Proteasome | Proteases/Proteasome; Ubiquitination |
BC-23 (NSC 45382) 是一种有效的蛋白酶体抑制剂,具有抗肿瘤和抗菌活性。BC-23 抑制蛋白酶体的 CT-L 活性,可用于研究白血病,淋巴瘤,神经胶质瘤,乳腺癌和小细胞肺癌。 | |||
T70759 |
CUDC-907 mesylate
|
||
CUDC-907 mesylate is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies. | |||
T16131 |
MPT0E028
|
Others | Others |
MPT0E028 is an orally active and selective inhibitor of HDAC (IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2, and HDAC6, respectively). MPT0E028 has good anticancer activity. MPT0E028 decreases the viability of B-cell lymphomas by inducing apoptosis | |||
T77008 | Finotonlimab | ||
Finotonlimab (SCT-I10A),一种重组人源化PD-1抗体,具备对实体瘤或淋巴瘤进行研究的潜力。 | |||
T73498 |
EG-011
|
||
EG-011为首创且有效的Wiskott-Aldrich综合症蛋白(WASP)激活剂, 通过促进肌动蛋白聚合以激活WASP的自抑制形式。此化合物展现出对淋巴瘤的选择性抗癌活性。 | |||
T35643 |
4-hydroperoxy Cyclophosphamide
4-hydroperoxy Cyclophosphamide,4-OOH-CY |
||
4-hydroperoxy Cyclophosphamide (4-OOH-CY) is the active metabolite form of the prodrug Cyclophosphamide. 4-OOH-CY crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS).[1] Formulations containing the prodrug Cyclophosphamide are used to treat lymphomas and autoimmune disorders.[2],[3] | |||
T75869 |
PSI TFA
|
||
PSI (TFA) 是一种有效的蛋白酶体proteasome 抑制剂。PSI (TFA) 抑制原发性渗出性淋巴瘤 (PEL) 细胞的增殖。PSI (TFA) 可用于卡波济氏肉瘤相关疱疹病毒 (KSHV) 感染和 KSHV 相关淋巴瘤的研究。 | |||
T76805 | Epratuzumab | ||
Epratuzumab(Antibody hLL 2)是一种针对CD22的IgG1型单克隆抗体,功能包括肿瘤成像和免疫调节。它能够诱发CD22磷酸化,主要应用于非霍奇金淋巴瘤和若干自身免疫性疾病的研究中。 | |||
T77823 |
Polatuzumab vedotin
|
||
Polatuzumab vedotin是一种抗体药物偶联物,靶向CD79b。该化合物结合了人源化抗CD79b IgG1单克隆抗体和微管抑制剂monomethyl auristatin E (MMAE),展现出针对大B细胞淋巴瘤(LBCL)的治疗潜力。 | |||
T60758 |
Tubulin polymerization-IN-36
|
||
Tubulin polymerization-IN-36 可用于癌症研究,例如淋巴癌。Tubulin polymerization-IN-36 结合微管蛋白的秋水仙碱位点并且抑制秋水碱结合,是一种微管蛋白聚合的抑制剂,IC50值为 2.8 μM。 | |||
T76729 | Lucatumumab | ||
Lucatumumab (HCD122) 是一种全人抗 CD40拮抗剂单克隆抗体,可阻断 CD40/ CD40L 介导的信号通路。Lucatumumab 可有效介导抗体依赖性细胞介导的细胞毒性 (ADCC) 和肿瘤细胞清除,可用于顽固性淋巴瘤、慢性淋巴细胞白血病 (CLL) 和多发性骨髓瘤研究。 | |||
T73700 |
Daunorubicin citrate
|
||
Daunorubicin citrate(Daunomycin citrate)作为一种拓扑异构酶 II(topoisomerase II)抑制剂,展现出有效的抗肿瘤活性,通过抑制 DNA 和 RNA 合成(DNA and RNA synthesis)发挥作用。作为一种细胞毒性药物,Daunorubicin citrate 能够抑制癌细胞活性,并诱导细胞凋亡(apoptosis)和坏死(necrosis),属于蒽环类抗生素范畴。该化合物广泛应用于包括白血病、非霍奇金淋巴瘤、尤文氏肉瘤、维尔姆斯氏瘤在内的多种癌症和感染研究领域。 | |||
T21763 | Lenalidomide hydrochloride | ||
Lenalidomide hydrochloride (CC-5013 hydrochloride) 是 Thalidomide 的衍生物,也是一种具有口服活性免疫调节剂,以分子胶的方式作用。Lenalidomide hydrochloride (CC-5013 hydrochloride) 是一种泛素 E3 连接酶 cereblon (CRBN) 的配体,通过 CRBN-CRL4 泛素连接酶对两种淋巴转录因子 IKZF1 和 IKZF3 进行选择性泛素化和降解。Lenalidomide hydrochloride (CC-5013 hydrochloride) 特异性抑制成熟 B 细胞淋巴瘤 (包括多发性骨髓瘤) 的生长,并诱导 T 细胞释放白细胞介素-2 (IL-2)。 | |||
T81942 |
Lenalidomide sodium
CC-5013 sodium |
||
Lenalidomide (sodium)是Thalidomide的衍生物,这种口服活性的免疫调节剂通过分子胶模式作用。作为泛素E3连接酶cereblon(CRBN)的配体,Lenalidomide (sodium)通过CRBN-CRL4泛素连接酶复合体,针对淋巴转录因子IKZF1和IKZF3进行选择性泛素化和降解。此外,Lenalidomide (sodium)有效抑制成熟B细胞淋巴瘤的增长,如多发性骨髓瘤,并能促使T细胞分泌白细胞介素-2(IL-2)。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T40859 |
5-Hydroxy-8-methoxypsoralen
5-Hydroxyxanthotoxin,5-Hydroxy-8-methoxypsoralen |
||
5-Hydroxy-8-methoxypsoralen (5-Hydroxyxanthotoxin) is a metabolite derived from Xanthotoxin, which acts as a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450). It is employed as an agent for the treatment of psoriasis, eczema, vitiligo, and certain cutaneous Lymphomas, in combination with phototherapy involving exposure to sunlight. |